Weight Loss After Receiving Anti‐Obesity Medications and Gout Among Individuals With Overweight and Obese: A Population‐Based Cohort Study
Authors' conclusion
A higher rate of weight loss after receiving treatment with orlistat within 1 year was associated with lower risks of incident gout and lower rates of recurrent gout flares among overweight or obese people.
Study context
- Population
- Individuals aged 18 and older, overweight or obese, starting anti-obesity medication (orlistat), Health Improvement Networkwithout gout, treated with orlistat
- Participants
- 131,000 individuals
- Exposure
- Slow, moderate or fast weight loss within the first year of anti-obesity medication vs weight gain or stability
- Outcome
- Incident gout and recurrent gout flares
- Follow-up
- 5 years
Methodological detailstarget trial emulation
- Target trial emulation
Main finding
As reported in the abstract
5-year risk of incident gout
Each group vs weight gain or stabilityHazard ratio (95% CI)
Slow
0.91(0.81–1.01)
Moderate
0.82(0.72–0.92)
Fast
0.73(0.62–0.86)
Observational data: associations, not effects.
Further findings
Recurrent gout flares (3,847 individuals with gout treated with orlistat)
- Similar results to incident gout
Original publication
Weight Loss After Receiving Anti‐Obesity Medications and Gout Among Individuals With Overweight and Obese: A Population‐Based Cohort Study. Arthritis Rheumatol. Published 11 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →